Articles published by Merck & Co., Inc.
Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Significantly Improved Overall Survival Versus Chemotherapy Alone in Patients With HER2-Negative Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma Regardless of PD-L1 Expression
February 16, 2023
Merck Announces Fourth-Quarter and Full-Year 2022 Financial Results
February 02, 2023
Merck Animal Health Receives U.S. FDA Approval of Expanded Indication for BRAVECTO (fluralaner) Chews for Dogs
January 26, 2023
Merck Completes Tender Offer to Acquire Imago BioSciences, Inc.
January 11, 2023
Merck to Hold Fourth-Quarter and Full-Year 2022 Sales and Earnings Conference Call February 2
January 05, 2023
Merck Begins Tender Offer to Acquire Imago BioSciences, Inc.
December 12, 2022
Merck to Present at the 5th Annual Evercore ISI HealthCONx Conference
November 21, 2022
Merck Announces Third-Quarter 2022 Financial Results
October 27, 2022
Robert M. Davis to Succeed Kenneth C. Frazier as Chairman of Merck
October 26, 2022